UNASSIGNED: Standard therapy for @entity3052 ( @entity3052 ) consists of @entity8 ( @entity8 ) including autologous- @entity8 (AUTO) and allogeneic- @entity8 from a matched-sibling donor (MSD) or well-matched unrelated donor (WM-URD). When a conventional donor is not available, @entity8 from a partially-matched (PM)-URD or @entity5527 ( @entity5527 ) is typically considered. We analyzed 561 @entity1 with intermediate to poor-risk molecular cytogenetics who underwent transplant from 2002 to 2013 in their first remission. Engraftment was successful in all donor types except five @entity1 who died in @entity3894 . Disease-free survival (DFS) at 5 years was 61.4% for MSD, 62.1% for WM-URD, 65.3% for @entity5527 , 44.7% for AUTO and 36.8% for PM-URD. AUTO showed the highest relapse rate (51.0%) compared to MSD (23.5%) and @entity5527 (18.5%), but showed the lowest 5-year non-relapse mortality (NRM) rate (3.8%). PM-URD showed the highest NRM (29.3%) with more instances of acute @entity2132 ( @entity2132 ) with grade>= III (29.3%), compared to MSD (15.6%) and @entity5527 (15.7%). In a poor-risk subgroup, the 5-year DFS for @entity5527 and MSD was 59.8% and 46.7%, respectively, while for AUTO and PM-URD it was 12.6% and 0.0%, respectively, which was caused by a high relapse rate (87.1% in AUTO, 83.3% in PM-URD). In the intermediate-risk subgroup, the 5-year DFS of AUTO (53.9%) was not different from the conventional donors in multivariate analysis, presenting a low NRM rate (5.1%). @entity5527 should be considered prior to PM-URD in intermediate-to-poor-risk @entity3052 and @entity2132 prophylaxis should be intensified when PM-URD is needed. AUTO might be considered for selected @entity1 in the intermediate-risk group.

Long-term clinical outcomes of @entity8 for intermediate-to-poor-risk XXXX during first remission according to available donor types.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['HCT', 'hematopoietic cell transplantation'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity5527 :: ('MESH:C536928', 'Disease') :: ['familial-mismatched donor', 'FMMD'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['graft-vs.-host disease', 'GVHD'] @entity3894 :: ('MESH:C563261', 'Disease') :: ['aplasia']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
